<p>AstraZeneca’s takeout of single-asset spinout TeneoTwo for $100 million up front is but the latest payout to shareholders in TeneoBio, who could stand to see even more upside in the years ahead, says Associate Editor Paul Bonanos on the latest edition of the BioCentury This Week podcast. Bonanos and the BioCentury editors also discuss how TeneoTwo investor Lightspeed Venture Partners has <a href='https://www.biocentury.com/article/643908/after-forty-seven-takeout-macquitty-finding-freedom-with-lightspeed-team'>deepened its commitment</a> to life sciences investing; Arch Venture Partners’ <a href='https://www.biocentury.com/article/644236'>plans</a> to deploy its new $3 billion venture fund; and the latest translational highlights from BioCentury’s <a href='https://www.biocentury.com/analysis/distillery-auth'>Distillery</a> and <a href='https://www.biocentury.com/article/644264'>Translational in Brief</a> sections. Plus: A preview of BioCentury&apos;s fall conference.</p>

Ep. 128 - Financial Markets Forecast, AAV Toxicity & Drug Pricing

BioCentury's streaming commentary on biotech industry trends, plus interviews with KOLs.For three decades, BioCentury has helped biopharma executives and investors make business-critical decisions and build larger networks with peers across the innovation ecosystem.